FindTrial
Sign In

Multicenter, Randomized, Parallel Controlled Study on the Efficacy and Safety of Modified Zhenwu Decoction in the Treatment of Chronic Heart Failure (Heart-Kidney Yang Deficiency Type)

Multicenter, Randomized, Parallel Controlled Study on the Efficacy and Safety of Modified Zhenwu Decoction in the Treatment of Chronic Heart Failure (Heart-Kidney Yang Deficiency Type)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001759
Enrollment
Unknown
Registered
2026-07-16
Start date
2026-03-03
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure

Interventions

Control Group::Conventional Western medicine
Experimental Group:Conventional Western medicine + Modified Zhenwu Decoction

Sponsors

First Affiliated Hospital of Guangzhou University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. History of chronic heart failure =3 months or clinical heart failure symptoms =3 months, meeting diagnostic criteria from 'Chinese Guidelines for Diagnosis and Treatment of Heart Failure (2024)'. 2. Age 18-80 years. 3. Meeting TCM diagnostic criteria for heart-kidney yang deficiency syndrome. 4. Received =2 weeks of fixed-dose conventional Western medication without vasoactive drugs or intravenous diuretics. 5. No Chinese medicine for heart failure used within 2 weeks before enrollment. 6. Voluntary participation with signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Acute cardiac insufficiency. 2. Cardiogenic shock, life-threatening arrhythmias, sinoatrial/AV block above type II without pacemaker, obstructive/restrictive cardiomyopathy, cor pulmonale, congenital heart disease, significant hemodynamic changes from uncorrected valvular disease, aortic aneurysm/dissection, constrictive pericarditis, myocarditis, cardiac tamponade, pulmonary embolism, progressive unstable angina, or acute myocardial infarction. 3. Severe pulmonary/hepatic/renal dysfunction: ALT/AST/ALP/creatinine >2×ULN; serum potassium >5.5mmol/L; severe endocrine/hematologic diseases. 4. Dysphagia or gastrointestinal disorders affecting drug absorption (e.g., GERD, chronic diarrhea, IBD, intestinal tuberculosis, etc.). 5. Pregnancy/lactation. 6. Malignancy, psychiatric disorders, or uncooperative patients. 7. Participation in other drug trials within 1 month. 8. Unable to complete 6MWT. 9. Investigator-deemed ineligibility.

Design outcomes

Primary

MeasureTime frame
NT-proBNP;—

Secondary

MeasureTime frame
Minnesota QOL Score;Cardiac Function Classification;6MWD Test;Traditional Chinese Medicine (TCM) Syndrome Efficacy;Cardiac Function Classification;Endpoint Events;Cardiac Chamber/Artery Dimensions;—

Countries

China

Contacts

Public ContactWang Dawei

First Affiliated Hospital of Guangzhou University of Chinese Medicine

13902236233@139.com13902236233

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Aug 10, 2026